Page 16 - FLIPBOOK

Androgen-deprivation therapy in prostate cancer and

cardiovascular risk: a science advisory from the American Heart
Association, American Cancer Society, and American Urological
Association: endorsed by the American Society for Radiation

Oncology.
Levine et al. Circulation 2010;121;833-840;

▪ Proven impact on standard CV risk factor

▪ Proven impact on CV events

▪ Disputable effect of CV death

[10-20-2010] The U.S. Food and Drug Administration (FDA) has notified the manufacturers of the Gonadotropin-

Releasing Hormone (GnRH) agonists of the need to add new safety information to the Warnings and Precautions section
of the drug labels. This new information warns about increased risk of diabetes and certain cardiovascular diseases (heart
attack, sudden cardiac death, stroke) in men receiving these medications for the treatment of prostate cancer.